Active, Not Recruiting

Trial ID CA047-004 | NCT04349267

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Sorry, this study is no longer accepting new participants, but is still ongoing.

You may click the “Check Your Eligibility” button and answer a few questions about your health to find out if you might be a match to another study.

Check Your Eligibility

Summary

The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.

Participants must have histologic confirmation of advanced (metastatic, recurrent, and/or unresectable) squamous cell carcinoma of the head and neck (SCCHN), nonsmall cell lung cancer (NSCLC), or renal cell cancer (RCC) with measurable disease per RECIST 1.1
Participants expected to have received standard of care therapies including an available PD-(L)1 inhibitor
Eastern cooperative oncology group performance status of 0 or 1
Women of childbearing potential must agree to follow methods of contraception

Participants with active, known or suspected autoimmune disease
Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
Uncontrolled or significant cardiovascular disease
History of or with active interstitial lung disease or pulmonary fibrosis
Prior participation in anti-natural killer cell receptor (anti-NKG2A) clinical study
History of allergy or hypersensitivity to study drug components Other protocol-defined inclusion/exclusion criteria apply

Additional Information *

Study Arms

Experimental: BMS-986315

ASSIGNED INTERVENTION

Study Arms

Experimental: BMS-986315 + cetuximab

ASSIGNED INTERVENTION

Study Arms

Experimental: BMS-986315 + nivolumab

ASSIGNED INTERVENTION